7 (70.00) 14 (77.78)≥65 yrs. 3 (30.00) 4 (22.22) Sex-no. (%) Male 5 (50.00) 9 (50.00) Female 5 (50.00) 9 (50.00)Metastatic sites-no. (%)Liver 4 (40.00) 1 (5.56)Lung 0 4 (22.22)Liver & lung 5 (50.00) 5 (27.78) Bone 1 (10.00) 2 (11.11) ECOG performance-status score-no. (%)0 5 (50.00) 2 (12.50)1 5 (50.00) 14 (87.50)Radiofrequency ablation-no. (%)Lung 1 (10.00) 0 Lung & liver 4 (40.00) 0 Liver 5 (50.00) 0Lines of prior systematic therapy-no. (%)2 3 (30.00) 6 (33.33)≥3 7 (70.00) 12 (66.67) Tumor type-no. (%)Colon Cancer 5 (50.00) 3 (16.67) Melanoma 1 (10.00) 3 (16.67) Lung Cancer 1 (10.00) 3 (16.67) Pancreatic Cancer 1 (10.00) 2 (11.11) Biliary Tract Cancer 1 (10.00) 1 (5.56) Ovarian Cancer 0 2 (11.11)Breast Cancer 0 2 (11.11)Others 1 (10.00) 2 (11.11)Shou et al. 10.3389/ ﬁmmu.2022.1000681 Frontiers in Immunology frontiersin.org 05 TABLE 2 Treatment related adverse events in all treated patients. RFA+Vac Patients (n = 10) Vac Patients (n = 18) Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 No. % No.